Reader sentiment, not investment advice. One vote per visitor; click again to change it.
MEDP is priced at $611.90 right now, down 1.97% on the session. That puts its market value at $17.08B, 629th largest among the 800 stocks we cover.
Over the past 52 weeks it has traded between $373.00 and $677.90, so it sits 9.7% below the top of that range.
Buyers are paying 36.0 times trailing earnings. The median for its industry group is 39.9.
9 analysts follow the stock and the average call is "hold". The mean target, $629.86, sits 2.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper on P/E than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
9 analysts, consensus Hold.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
MEDP is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $629.86, 2.9% above today’s price, with a consensus rating of Hold.
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 36.0x earnings, MEDP looks expensive against the market, and trades 10% below the 39.9x median among Diagnostics & Research names. The two comparisons do not always agree.
$611.90 is the latest print for MEDP, a move of -1.97% against yesterday's close of $624.18. Today's low and high so far: $611.04 and $628.04.
Equity value comes to $17.08B at the current price. By that measure it is number 629 of the 800 names in our coverage.
Buyers pay 36.0 times the last twelve months of profit (EPS $15.28).
The year's floor is $373.00 and the ceiling $677.90. Shares are 9.7% away from that ceiling.
Our data shows no dividend paid by Medpace over the trailing twelve months.
Of 9 analysts, 22% say buy, 78% hold and 0% sell. Price targets average $629.86, with the most cautious at $535.00 and the most optimistic at $692.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MEDP.